[HTML] nih.gov

[HTML][HTML] Improving susceptibility of neuroendocrine tumors to radionuclide therapies: personalized approaches towards complementary treatments

S Richter, C Steenblock, A Fischer, S Lemm… - Theranostics, 2024 - ncbi.nlm.nih.gov
Radionuclide therapies are an important tool for the management of patients with
neuroendocrine neoplasms (NENs). Especially [131 I] MIBG and [177 Lu] Lu-DOTA-TATE …
相关文章

Improving susceptibility of neuroendocrine tumors to radionuclide therapies: personalized approaches towards complementary treatments

S Richter, C Steenblock, A Fischer, S Lemm… - …, 2024 - search.proquest.com
Radionuclide therapies are an important tool for the management of patients with
neuroendocrine neoplasms (NENs). Especially [131I] MIBG and [177Lu] Lu-DOTA-TATE are …

Improving susceptibility of neuroendocrine tumors to radionuclide therapies: personalized approaches towards complementary treatments

S Richter, C Steenblock, A Fischer, S Lemm… - …, 2024 - pubmed.ncbi.nlm.nih.gov
Radionuclide therapies are an important tool for the management of patients with
neuroendocrine neoplasms (NENs). Especially [131 I] MIBG and [177 Lu] Lu-DOTA-TATE …

[引用][C] Improving susceptibility of neuroendocrine tumors to radionuclide therapies: personalized approaches towards complementary treatments

S Richter, C Steenblock, A Fischer, S Lemm… - europepmc.org
Radionuclide therapies are an important tool for the management of patients with
neuroendocrine neoplasms (NENs). Especially [131I] MIBG and [177Lu] Lu-DOTA-TATE are …

Improving susceptibility of neuroendocrine tumors to radionuclide therapies: personalized approaches towards complementary treatments

S Richter, C Steenblock, A Fischer, S Lemm… - Theranostics, 2024 - zora.uzh.ch
Radionuclide therapies are an important tool for the management of patients with
neuroendocrine neoplasms (NENs). Especially [$^{131} $ I] MIBG and [$^{177} $ Lu] Lu …